Neuroprotective effects of modafinil in a marmoset Parkinson model: Behavioral and neurochemical aspects

Behavioural Pharmacology

Volumn 17, Issue 5-6, 2006, Pages 453-462

  Van Vliet, Sanneke A M ^a,b   Vanwersch, Raymond A P ^a   Jongsma, Marjan J ^a   Van Der Gugten, Jan ^b   Olivier, Berend ^b   Philippens, Ingrid H C H M ^a  

^a TNO   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

1 methyl 1,2,3,6 tetrahydropyridine; Behavior; Marmoset; Modafinil; Monoamines; Neuroprotection; Parkinson's disease

Indexed keywords

BRAIN MONOAMINE; DOPAMINE; MODAFINIL; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; BODY MOVEMENT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG EFFECT; DRUG EFFICACY; EYE HAND COORDINATION; FEMALE; LOCOMOTION; MALE; MARMOSET; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; STARTLE REFLEX; STATISTICAL ANALYSIS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADMINISTRATION, ORAL; ANIMALS; AROUSAL; BENZHYDRYL COMPOUNDS; CALLITHRIX; CORPUS STRIATUM; DOPAMINE; HUMANS; MALE; MOTOR ACTIVITY; MOTOR SKILLS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PSYCHOMOTOR PERFORMANCE; STARTLE REACTION;

EID: 33748294247     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200609000-00011     Document Type: Article

References (48)

1. Adams LM, Geyer MA (1981). Effects of 6-hydroxydopamine lesions of locus coerulus on startle in rats. Psychopharmacology 73:394-398.
2. Alexi T, Borlongan CV, Faull RL, Williams CE, Clark RG, Gluckman PD, Hughes PE (2000). Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog Neurobiol 60:409-470.
3. Antonelli T, Ferraro L., Hillion J., Tomasini MC., Rambert FA., Fuxe F (1998). Modafinil prevents glutamate cytotoxicity in cultured cortical neurons. Neuroreport 9:4209-4213.
4. Bastuji H, Jouvet M (1988). Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 12:695-700.
5. Bezard E, Gross CE (1998). Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol 55:93-116.
6. Braak H, Del Tredici K, Rub U, de Vos RAI, Jansen Steur ENH, Braak E (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
7. Carey GJ, Costall B, Domeney AM, Jones DN, Naylor RJ (1992). Behavioural effects of anxiogenic agents in the common marmoset. Pharmacol Biochem Behav 42:143-153.
8. Clarke CE (2004). Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol 3:466-474.
9. Dauer W, Przedborski S (2003). Parkinson's disease: mechanisms and models. Neuron 39:889-909.
10. Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ (2000). Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 15:459-466.
11. Duteil J, Rambert FA, Pessonnier J, Hermant JF, Gombert R, Assous E (1990). Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol 180:49-58.
12. Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K (1996). The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 220:5-8.
13. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K (1997). The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 8:2883-2887.
14. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K (1998). The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 253:135-138.
15. Ferraro L, Fuxe K, Tanganelli S, Tomasini MC, Rambert FA, Antonelli T (2002). Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res 68:107-112.
16. Fuxe K, Janson AM, Rosen L, Finnman U-B, Tanganelli S, Morari M, et al. (1992). Evidence for a protective action of the vigilance promoting drug Modafinil on the MPTP-induced degeneration of nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. Exp Brain Res 88:117-130.
17. Guy W (1976). ECDEU assessment manual for psychopharmacology. Washington DC: US Department of Health, Education and Welfare; pp. 534-537.
18. Jenner P, Marsden CD (1986). The actions of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in animals as a model of Parkinson's disease. J Neural Transm Suppl 20:11-39.
19. Jenner P, Zeng BY, Smith LA, Pearce RK, Tel B, Chancharme L, Moachon G (2000). Antiparkinsonian and neuroprotective effects of modafinil in the MPTP-treated common marmoset. Exp Brain Res 133:178-188.
20. Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ (2004). Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J Neurol Neurosurg Psychiatry 75:295-297.
21. Kupsch A, Sautter J, Gotz ME, Breithaupt W, Schwartz J, Youdim MB, et al. (2001). Monoamine-oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012). with selegiline. J Neural Transm 108:985-1009.
22. Kurosaki R, Muramatsu Y, Kato H, Araki T (2004). Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease. Pharmacol Biochem Behav 78:143-153.
23. Lallement G, Pierard C, Masqueliez C, Baubichon D, Pernot-Marino I, Peres M, Lagarde D (1997). Neuroprotective effect of modafinil against soman-induced hippocampal lesions. Med Sci Res 25:437-440.
24. Leng A, Yee BK, Feldon J, Ferger B (2004). Acoustic startle response, prepulse inhibition, and spontaneous locomotor activity in MPTP-treated mice. Behav Brain Res 154:449-456.
25. Mackenzie GM, Jackson MJ, Jenner P, Marsden CD (1997). Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset. Synapse 26:301-316.
26. Nieuwenhuijzen PH, Horstink MW, Bloem BR, Duysens J (2005). Startle response in Parkinson patients during human gait. Exp Brain Res; Online November 24, 1-10.
27. Perez-Otano I, Herrero MT, Oset C, De Ceballos ML, Luquin MR, Obeso JA, Del Rio J (1991). Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res 567:127-132.
28. Philippens IH, Melchers BP, Roeling TA, Bruijnzeel PL (2000). Behavioral test systems in marmoset monkeys. Behav Res Methods Instrum Comput 32:173-179.
29. Robertson P Jr, Hellriegel ET (2003). Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 42: 123-137.
30. Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD (1989). Increased dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci Lett 101:305-310.
31. Rose S, Nomoto M, Jackson EA, Gibb WRG, Jaehnig P, Jenner P, Marsden CD (1993). Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur J Pharm 230:177-185.
32. Russ H, Mihatsch W, Gerlach M, Riederer P, Przuntek H (1991). Neurochemical and behavioral features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease? Neurosci Lett 123:115-118.
33. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983). Reduction of cortical dopamine, noradrenaline and serotonin and their metabolites in Parkinson's disease. Brain Res 275:321-328.
34. Schmidt N, Ferger B (2001). Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 108:1263-1282.
35. Stevenson MF, Poole TB (1976). An ethogram of the common marmoset (Calithrix jacchus jacchus): general behavioural repertoire. Anim Behav 24:428-451.
36. Sundstrom E, Jonsson G (1986). Differential time course of protection by monoamine oxidase inhibition and uptake inhibition against MPTP neurotoxicity on central cathecholamine neurons in mice. Eur J Pharmacol 122:175-178.
37. Teismann P, Tieu K, Cohen O, Choi DK, Wu du C, Marks D, et al. (2003). Pathogenic role of glial cells in Parkinson's disease. Mov Disord 18:121-129.
38. Touret M, Sallonon-Moulin M, Fages C, Roudier V, Didier-Bazes M, Roussel B, et al. (1994). Effects of modafinil-induced wakefullness on glutamine synthase regulation in the rat brain. Mol Brain Res 26:123-128.
39. Ueki A, Rosen L, Andbjer B, Agnati LF, Hallstrom A, Goiny M, et al. (1993a). Evidence for a preventive action of the vigilance-promoting drug modafinil against striatal ischemic injury induced by endothelin-1 in the rat. Exp Brain Res 96:89-99.
40. Ueki A, Rosen L, Andbjer B, Funmann U-B, Altamimi U, Janson AM, et al. (1993b). The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transsection of the dopamine pathway. Exp Brain Res 93:259-270.
41. Van Vliet SA, Jongsma MJ, Vanwersch RA, Olivier B, Philippens IH (2005). Human threat test: a method to test anxiety related behavior in the marmoset monkey. In: Noldus LP, et al. editors. Proceedings of measuring behavior. Wageningen: Noldus Information Technology; pp. 472-473.
42. Van Vliet SA, Jongsma MJ, Vanwersch RA, Olivier B, Philippens IH (2006). Behavioral effects of modafinil in marmoset monkeys. Psychopharmacology, Online March 21.
43. Vidailhet M, Rothwell JC, Thompson PD, Lees AJ, Marsden CD (1992). The auditory startle response in the Steel-Richardson-Olszewski syndrome and Parkinson's disease. Brain 115:1181-1192.
44. von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, et al. (2004). Loss of locus coerulus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci USA 101:10744-10749.
45. Waters CM, Hunt SP, Jenner P, Marsden CD (1987). An immunohistochemical study of the acute and long-term effects of 1-methylphenyl-1,2,3,6- tetrahydropyridine in the marmoset. Neuroscience 23:1025-1039.
46. Wichmann T, DeLong MR (1998). Models of basal ganglia function and pathophysiology of movement disorders. Neurosurg Clin North Am 9:223-236.
47. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM (2001). Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21:1787-1794.
48. Wolthuis OL, Groen B, Philippens IH (1994). A simple automated test to measure exploratory and motor activity of marmosets. Pharmacol Biochem Behav 47:879-881.